retatrutide fat loss trial 🚨 BREAKING: Shows “Bariatric-Level” Weight in Phase 3 New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Retatrutide Phase 3: 60% Achieved

There is a plan to share other data

N., Calton, E

The 12mg dose reduced systolic blood pressure by an average of 14.0 mmHg

Weight Regain: A Common Challenge Studies show that discontinuing GLP-1 agonists frequently leads to weight regain and a return of cardiometabolic issues that improved while on the medication.(3, 4) An analysis of 327 individuals who used GLP-1 medication for 68 weeks found that after stopping the treatment, they regained approximately two-thirds of the weight they had initially lost

Rather than immediately jumping into a 16:8 fast while initiating Retatrutide at standard doses, many practitioners recommend establishing tolerance to each intervention before combining them at full intensity

[DOI] [PMC free article] [PubMed] [Google Scholar] 68.Chen S.-Y., Kong X.-Q., Zhang K.-F., Luo S., Wang F., Zhang J.-J